☆ 4.7 Article

Effect of sotagliflozin on ventricular arrhythmias in mice with myocardial infraction

EUROPEAN JOURNAL OF PHARMACOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Cell Biology

Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis

Kai Jiang et al.

Summary: SGLT2 inhibitor Empagliflozin (EMPA) has been shown to suppress cardiomyocyte autophagic cell death, reduce infarct size, improve cardiac function and survival, by inhibiting Na+/H+ exchanger 1 (NHE1) activity and regulating excessive autophagy. These findings provide new insights for drug development targeting NHE1 and autophagy for ventricular remodeling and heart failure treatment after myocardial infarction in both diabetic and non-diabetic patients.

PROTEIN & CELL (2022)

Add to Collection

Review Pharmacology & Pharmacy

Sodium glucose cotransporter 1 (SGLT1) inhibitors in cardiovascular protection: Mechanism progresses and challenges

Yebei Li et al.

Summary: Recent clinical trials have shown that SGLT1 inhibitors have significant cardiovascular benefits, although the exact mechanisms are not completely understood. Potential explanations include reducing oxidative stress, regulating cardiac glucose uptake, and preventing ischemia/reperfusion injury.

PHARMACOLOGICAL RESEARCH (2022)

Add to Collection

Article Chemistry, Multidisciplinary

Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1/MAPK signaling

Ke Lin et al.

Summary: This study investigated the protective effect of Dapa against obesity-related cardiomyopathy caused by a high fat diet. The results showed that Dapa can reduce cardiomyocyte hypertrophy, fibrosis, and apoptosis, and alleviate cardiac dysfunction and remodeling caused by obesity. This protective effect is achieved through the inhibition of the MAPK/AP-1 pathway and improvement of cardiac inflammation. These findings highlight the potential use of Dapa in the prevention of obesity-related cardiac dysfunction.

ACTA PHARMACOLOGICA SINICA (2022)

Add to Collection

Article Cell Biology

Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression

Nabeel Abdulrahman et al.

Summary: Diabetes-induced cardiac morbidities are the leading cause of death among diabetic patients. Recent studies have shown that the drug empagliflozin, which is used to treat diabetes, has a cardioprotective effect. In this study, the researchers found that empagliflozin reduces cardiac hypertrophy by inhibiting the expression of certain proteins.

MOLECULAR AND CELLULAR BIOCHEMISTRY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF

David Bode et al.

Summary: This study found that the SGLT-1&2 inhibitor sotagliflozin improved left atrial remodeling in a metabolic HFpEF rat model, reduced the occurrence of cellular arrhythmias, and enhanced mitochondrial function. These effects may be related to the inhibition of sodium-calcium exchanger (NCX) forward-mode activity.

CARDIOVASCULAR DIABETOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Targeting 5-HT2B Receptor Signaling Prevents Border Zone Expansion and Improves Microstructural Remodeling After Myocardial Infarction

J. Caleb Snider et al.

Summary: Inhibiting 5-HT2B can reduce fibrotic scar formation after MI, thereby protecting cardiac structure and function. The redistribution of collagen fibers to thinner, more anisotropic fibers enhances left ventricular contractility, while decreasing fibrotic tissue stiffness limits the hypertrophic response of uninjured cardiomyocytes. Ablation of 5-HT2B in cardiac fibroblasts or myofibroblasts contributes to excessive scar formation and impairs cardiac function after MI.

CIRCULATION (2021)

Add to Collection

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Deepak L. Bhatt et al.

Summary: In patients with diabetes and recent worsening heart failure, treatment with sotagliflozin significantly reduced the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure compared to placebo, regardless of the timing of administration.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Pharmacology & Pharmacy

Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice

Yihai Liu et al.

Summary: The study demonstrated that the SGLT2 inhibitor empagliflozin could improve cardiac remodeling in early myocardial infarction of non-diabetic mice by reducing cardiomyocyte apoptosis, oxidative stress, and restoring mitochondrial membrane potential. The activation of AMP-activated protein kinase (AMPK) signaling pathway may mediate the cardioprotective role of empagliflozin.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)

Add to Collection

Editorial Material Pharmacology & Pharmacy

Sotagliflozin and decompensated heart failure: results of the SOLOIST-WHF trial

Syed Raza Shah et al.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Low-Dose Empagliflozin Improves Systolic Heart Function after Myocardial Infarction in Rats: Regulation of MMP9, NHE1, and SERCA2a

Jana Goerg et al.

Summary: The study found that low-dose empagliflozin can increase cardiac contractility in normoglycemic rats and improve heart function early after myocardial infarction. These effects are achieved through the down-regulation of MMP9 and NHE1, as well as the up-regulation of SERCA2a, indicating a potential treatment option to improve cardiovascular outcomes post-MI.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Medicine, Research & Experimental

Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia

Mohammed Ali Azam et al.

Summary: The study found that EMPA treatment can reduce ventricular arrhythmia vulnerability, improve cardiac contractile function, and enhance calcium cycling and mitochondrial redox through SGLT2-independent mechanisms in a global ischemia-reperfusion model.

LIFE SCIENCES (2021)

Add to Collection

Article Physiology

Sotagliflozin, a Dual SGLT1/2 Inhibitor, Improves Cardiac Outcomes in a Normoglycemic Mouse Model of Cardiac Pressure Overload

Sophia L. Young et al.

Summary: Selective SGLT2 inhibition reduces the risk of worsening heart failure and cardiovascular death in patients with existing heart failure, regardless of diabetic status. The study demonstrates the utility of dual SGLT1/2 inhibition in treating cardiac injury induced by pressure overload in normoglycemic mice, but its efficacy in high fat-fed mice with mild hyperglycemia and compromised renal morphology requires further study.

FRONTIERS IN PHYSIOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction-induced ventricular remodeling and heart failure in mice

Yohei Sawa et al.

JOURNAL OF PHARMACOLOGICAL SCIENCES (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Empagliflozin prevents doxorubicin-induced myocardial dysfunction

Jolanda Sabatino et al.

CARDIOVASCULAR DIABETOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Empagliflozin improves left ventricular diastolic function of db/db mice

Julia Moellmann et al.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury

Sarayut Lahnwong et al.

CARDIOVASCULAR DIABETOLOGY (2020)

Add to Collection

Article Pharmacology & Pharmacy

Shensong Yangxin Protects Against Metabolic Syndrome-Induced Ventricular Arrhythmias by Inhibiting Electrical Remodeling

Hong-Jie Yang et al.

FRONTIERS IN PHARMACOLOGY (2020)

Add to Collection

Review Cardiac & Cardiovascular Systems

SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control

Martin R. Cowie et al.

NATURE REVIEWS CARDIOLOGY (2020)

Add to Collection

Article Pharmacology & Pharmacy

Chronic sigma-1 receptor activation ameliorates ventricular remodeling and decreases susceptibility to ventricular arrhythmias after myocardial infarction in rats

Yuhong Fo et al.

EUROPEAN JOURNAL OF PHARMACOLOGY (2020)

Add to Collection

Article Pharmacology & Pharmacy

Loss of MD1 exacerbates myocardial ischemia/reperfusion injury and susceptibility to ventricular arrhythmia

Xiaobo Jiang et al.

EUROPEAN JOURNAL OF PHARMACOLOGY (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction

Salva R. Yurista et al.

EUROPEAN JOURNAL OF HEART FAILURE (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Loss of MD1 increases vulnerability to ventricular arrhythmia in diet-induced obesity mice via enhanced activation of the TLR4/MyD88/CaMKII signaling pathway

Wei Shuai et al.

NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)

Borja Ibanez et al.

EUROPEAN HEART JOURNAL (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction

Kim A. Connelly et al.

CARDIOVASCULAR DIABETOLOGY (2018)

Add to Collection

Review Cardiac & Cardiovascular Systems

Metabolic Coordination of Physiological and Pathological Cardiac Remodeling

Andrew A. Gibb et al.

CIRCULATION RESEARCH (2018)

Add to Collection

Review Biochemistry & Molecular Biology

Role of Non-Myocyte Gap Junctions and Connexin Hemichannels in Cardiovascular Health and Disease: Novel Therapeutic Targets?

Robert D. Johnson et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)

Add to Collection

Review Cardiac & Cardiovascular Systems

Traditional and novel electrocardiographic conduction and repolarization markers of sudden cardiac death

Gary Tse et al.

EUROPACE (2017)

Add to Collection

Review Cell Biology

A Review of the Molecular Mechanisms Underlying the Development and Progression of Cardiac Remodeling

Leonardo Schirone et al.

OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2017)

Add to Collection

Article Multidisciplinary Sciences

Loss of MD1 exacerbates pressure overload-induced left ventricular structural and electrical remodelling

Jianye Peng et al.

SCIENTIFIC REPORTS (2017)

Add to Collection

Article Physiology

Cardiac Fibrosis and Arrhythmogenesis

My-Nhan Nguyen et al.

COMPREHENSIVE PHYSIOLOGY (2017)

Add to Collection

Review Physiology

Biology of Human Sodium Glucose Transporters

Ernest M. Wright et al.

PHYSIOLOGICAL REVIEWS (2011)

Add to Collection

Article Cardiac & Cardiovascular Systems

Structural and Molecular Mechanisms of Gap Junction Remodeling in Epicardial Border Zone Myocytes following Myocardial Infarction

Fabien Kieken et al.

CIRCULATION RESEARCH (2009)

Add to Collection

Review Physiology

Arrhythmogenic ion-channel remodeling in the heart: Heart failure, myocardial infarction, and atrial fibrillation

Stanley Nattel et al.

PHYSIOLOGICAL REVIEWS (2007)

Add to Collection

Review Nutrition & Dietetics

The glucose transporter families SGLT and GLUT:: Molecular basis of normal and aberrant function.

A Scheepers et al.

JOURNAL OF PARENTERAL AND ENTERAL NUTRITION (2004)

Add to Collection

Article Cardiac & Cardiovascular Systems

Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction

E Perrier et al.

CIRCULATION (2004)

Add to Collection

Article Cardiac & Cardiovascular Systems

Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in cx43-deficient mice

DL Lerner et al.

CIRCULATION (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.